Glaukos
GKOS | NYSE
$244.88
-$0.84 (-0.34%)
At close: Nov 16, 2026, 4:00 PM ET
$246.00
+$1.12 (+0.46%)
After-hours:
Nov 16, 2026, 7:33 PM ET
Glaukos Company Profile
Company profile explainedCompany Profile
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Key Executives
| Name | Position |
|---|---|
| Thomas William Burns | Chairman & Chief Executive Officer |
| Alex R. Thurman | Senior Vice President & Chief Financial Officer |
| Joseph E. Gilliam | President & Chief Operating Officer |
| Christopher William Lewis | Vice President of Investor Relations & Corporate Affairs |
| Diana A. Scherer | Vice President of Compliance & Deputy General Counsel |
| L. Jay Katz FACS | Chief Medical Officer |
| Michele Allegretto | Senior Vice President of Human Resources |
| Robert L. Davis | Senior Vice President, General Counsel & Business Development |
| Tomas Navratil | Chief Development Officer |
| Tracy Founds | Senior Vice President of Global Quality & Medical Safety |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | 10-Q | Quarterly Report |
| Oct 28, 2026 | 8-K | Current Report |
| Oct 07, 2026 | 4 | Filing |
| Sep 28, 2026 | 4 | Filing |
| Sep 18, 2026 | 4 | Filing |
| Sep 01, 2026 | 4 | Filing |
| Aug 20, 2026 | 4 | Filing |
| Aug 13, 2026 | 4 | Filing |
| Aug 11, 2026 | 4 | Filing |
| Aug 03, 2026 | 4 | Filing |
Glaukos
| Country | United States |
| IPO Date | Jun 25, 2015 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 1,094 |
| CEO | Thomas William Burns |
Contact Details
One Glaukos Way Aliso Viejo,
California 92656 United States
Stock Details
| Ticker Symbol | GKOS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001192448 |
| CUSIP Number | 377322102 |
| ISIN Number | US3773221029 |
| SIC Code | 3841 |
Recent News
- 18 days ago / fool.comGlaukos Sets $1 Billion 2027 Sales Goal: Rapid Earnings Reaction
- 19 days ago / benzinga.comWhy Glaukos Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
- 19 days ago / seekingalpha.comGlaukos Corporation (GKOS) Q3 2026 Earnings Call Transcript
- 19 days ago / zacks.comGlaukos (GKOS) Q3 Earnings and Revenues Surpass Estimates
- 19 days ago / zacks.comCompared to Estimates, Glaukos (GKOS) Q3 Earnings: A Look at Key Metrics
- 19 days ago / marketbeat.comGlaukos Q3 Earnings Call Highlights
- 1 month ago / zacks.comGlaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?
- 1 month ago / seekingalpha.comGlaukos: The Second J-Code Rewrites The Risk Math
- 1 month ago / zacks.comGlaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal
- 1 month ago / benzinga.comGlaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy
Add to Watchlist
Select watchlists to add or remove GKOS